News & Updates

Show Multimedia Only

$Low BMD, fracture risk upped in childhood cancer survivors$

Low BMD, fracture risk upped in childhood cancer survivors

25 Jan 2023 by

Childhood cancer survivors (CCS) appear to have an increased risk of low bone mineral density (BMD) and fracture compared with the general population, according to a cross-sectional study from the Netherlands.

25 Jan 2023

Immune checkpoint inhibitors carry some risk of hepatotoxicity

25 Jan 2023

The use of immune checkpoint inhibitors (ICIs) for the treatment of various cancers appears to have hepatotoxic effects, the risk of which is greater with ICI combination therapy than with monotherapy, as reported in a recent study.

25 Jan 2023

Objective response to systemic therapy linked to overall survival in unresectable HCC

23 Jan 2023 by

Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.

23 Jan 2023

Multiple moles, genetic predisposition up risk of second primary melanomas

22 Jan 2023

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

22 Jan 2023

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023 by

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

20 Jan 2023

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.

20 Jan 2023

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023 by

Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.

20 Jan 2023

Lung cancer ups mortality risk in IPF patients

19 Jan 2023

A diagnosis of lung cancer can significantly worsen survival in patients with idiopathic pulmonary fibrosis (IPF), reports a study.

19 Jan 2023

MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden

19 Jan 2023 by

Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.

19 Jan 2023

Digital misinformation may lead to wrong health decisions, says study

18 Jan 2023 by

An online cross-sectional survey involving antivaxxers, conspiracy theorists, and flat earthers reveals how these people are more likely to believe in false causes of cancer, indicating an association between digital misinformation and consequent erroneous health decisions.

18 Jan 2023

News & Updates

Showing Oncology articles

Showing

Specialty:

Low BMD, fracture risk upped in childhood cancer survivors

Immune checkpoint inhibitors carry some risk of hepatotoxicity

Objective response to systemic therapy linked to overall survival in unresectable HCC

Multiple moles, genetic predisposition up risk of second primary melanomas

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

Lung cancer ups mortality risk in IPF patients

MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden

Digital misinformation may lead to wrong health decisions, says study